drugset / Trial / NCT02173678
Safety and Tolerability of COMBIVENT® HFA as Compared to COMBIVENT® CFC and Placebo HFA in Healthy Male and Female Subjects
RandomizedCrossoverDouble-blindTreatment
Summary
Study to assess the safety and tolerability of COMBIVENT® hydrofluoroalkane (HFA) as compared to COMBIVENT® chlorofluorocarbons (CFC) and placebo HFA after single and repetitive dosing in healthy male and female subjects
Timeline
- Start
- 1999-10
- Primary completion
- 1999-11
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipratropium | Small molecule | 288 ug | Inhaled |
| Subject | Salbutamol | Unknown | 1600 ug | Inhaled |
| Subject | Salbutamol | Unknown | 1648 ug | Inhaled |
Indications
No indication recorded.